Allergy/Immunology
RSSArticles
-
Evaluation and Management of Anaphylaxis in the Emergency Department
This article will present the most current information for diagnosing allergic reactions and anaphylaxis and how to treat them properly.
-
Epinephrine Nasal Spray (Neffy)
The U.S. Food and Drug Administration has approved epinephrine nasal spray for the emergency treatment of allergic reactions, including anaphylaxis. It was granted a fast-track designation and will be distributed by ARS Pharmaceuticals as Neffy.
-
Oral Penicillin Challenge vs. Skin Testing: Diagnosing Low-Risk Patients with Reported Penicillin Allergy
In a comparison of direct oral penicillin challenge in low-risk patients to skin testing followed by oral challenge, researchers reported no significant differences. Direct oral penicillin challenge appears to be a safe and effective way to delabel a penicillin allergy.
-
Managing Anaphylaxis in the Emergency Department
The incidence of anaphylaxis, a rapidly progressive and potentially fatal disease, is increasing and unfortunately common in children. It is imperative that all acute care providers are prepared to recognize, quickly treat, and ensure appropriate follow-up for these patients. The authors focus on anaphylaxis, its presentation, management, and disposition from the ED.
-
Researchers Address HIV Treatment Gap Among Underserved Population
There are effective medications, but social determinants of health can dictate adherence.
-
Smallpox and Monkeypox Vaccine, Live, Non-Replicating (Jynneos)
Jynneos can be administered to prevent smallpox and monkeypox in adults age 18 years and older who are at high risk for contracting the infections.
-
COVID-19 and Headache
Headache is a common feature of acute COVID-19 infection, as well as a long-standing feature of “long COVID” after recovery from the acute infection. Treatment is symptomatic, based on the characteristics of the headache syndrome.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.
-
COVID-19 Rebound
Symptomatic and virologic recrudescence after treatment of patients with COVID-19 with Paxlovid occurs in a tiny percentage of patients and generally is mild and self-limited.
-
COVID-19 Pre-Exposure Prophylaxis
The combination of tixagevimab and cilgavimab (Evusheld) was demonstrated to be effective in the prevention of symptomatic COVID-19, but much remains to be learned as SARS-CoV-2 continues to evolve.